2023 - Nanbiosis

NANBIOSIS U1 at UAB Innovation Fair

On October 17, 2023, the NANBIOSIS U1 of Protein Production Platform PPP, took part in the UAB Innovation Fair, where various research groups, spin-offs, service providers, research centers, and companies gathered to foster networking opportunities.

This event proved highly advantageous for the PPP, as it not only facilitated the identification of potential new clients but also paved the way for collaborative efforts aimed at enhancing and refining the final product offered by the PPP.

In the picture PPP NANBIOSIS U1 Scientists at PPP stand at the Fair: Neus Ferrer, Scientific Director; Rosa Mendoza, Laboratory Manager, and Mercedes Marquez, Scientific Coordinator. — PPP NANBIOSIS U1 Scientists at PPP stand at the Fair: **Neus Ferrer, Scientific Director; Rosa Mendoza, Laboratory Manager, and Mercedes Marquez, Scientific Coordinator**.

The UAB Innovation Fair is a day for relations between the world of research and the business environment that aims to recognize the transfer of knowledge from research groups and show the wide range of technologies, services, innovative ideas and entrepreneurial projects generated on the UAB campus.

Its inauguration was in charge of Montserrat López Merlos, president of the Social Counsel Academic Commision, Lluis Juncà, director general director of Innovation of the Generalitat de Catalunya, Javier Lafuente, rector of the UAB.

The inauguration was followed by an inspirational talk on Innovation, trends and challenges by Jordi Puigneró, mayor deputy of Institutional Relations, Good Government and Digital City of Sant Cugat del Vallès City Council.

Ater a fruitful matchmaking session between research groups and startups and companies, a round table took place with biopharmaceutical companies “Company-University Collaboration, model for excellence” was organiced with the participation of:

Ignasi Belda, CEO of MiWEndo Solutions
Ferran Briansó, Innovation Projects Manager at Roche Diagnostics
Fabiana d’Aniello, R&D Director at Ferrer
Joaquim Mallorquí, Bioterapeutics R&D Director at Hipra
Montse Monsalvatje, Processes Deevelopment Director at Esteve
Moderador: Dani Cordero, Economy Manager of El País Catalunya

• Read More

The importance of bacterial Quorum Sensing (QS) research recognised in the Princesa of Asturias Awards

Today, Bonnie Bassler, Jeffrey Gordon, and Peter Greenberg are receiving the Princess of Asturias Award for their contribution to the knowledge of the role of the human microbiome and the bacteria Quorum Sensing.

Targeting Quorum Sensing allows understanding of bacteria behaviour and pathogenesis, but also developing new therapeutic and diagnostic strategies for infectious diseases.

Bonnie Bassler has shown how small chemical signals are involved in such a communication process.

Peter Greenberg was one of the first scientists who assigned the term Quorum Sensing (QS) to such a sophisticated system used by bacteria to communicate and synchronize behavior. He was involved on the discovery of the QS signalling pathways of important pathogens such as Pseudomonas aeruginosa and their implication on virulence and biofilm formation, key for the establishment of chronic and antibiotic-resistant infections

Jeffrey Gordon is a pioneer of microbiome research. These billions of bacteria living in our bodies have an extraordinary effect on our health, determining metabolic or even neurological disorders. His discoveries are tackling global issues such as childhood malnutrition.

The winners explained at the press conference the importance of this award:

“I couldn’t imagine that was going to be awarded the “Premio Princesa de Asturias” when I see those who have achieved it… they are icons, they are my idols in all kinds of fields!”, said Bonnie Bassler. Peter Greenberg explained that it is not only a recognition of the work done over many years in their research group but also of the work done by all the scientists in microbiology “This honor that has been granted to us is a recognition of how important microbiology and science in general is”.

From NANBIOSIS ICTS we want to congratulate the winners and thank the Princess of Asturias Foundation for the recognition of a piece of research which is of specific interest in our Unit 2-CAbS, research group Nb4D – from CIBER-BBN and IQAC-CSIC, led by M. Pilar Marco. Her research line is focused on the development of diagnostic and therapeutic strategies for infectious diseases targeting the aforementioned Quorum Sensing (QS) and based on antibody-funded technologies. The QS is a sophisticated cell communication system controlling a series of cellular processes involved in pathogenesis, based on the release and detection of small signaling molecules (QSsm).

• Read More

Developing Support Technologies for adressing traslational gaps in regenerative medicine.

On the 20th of October, CIBER-BBN group NanoBioCell – NANBIOSIS U10 Drug Formulation unit organises the Conference “Developping support technologies for adressing traslational gaps in regenerative medicine” by Dr. James-J Yoo.

The Conference will take place in the Assembly hall of the Faculty of Pharmacy on Friday 20th of October, 2023 from 12:00 to 13:00, as part of the JRL program Advanced Pharma Development. The Conference will be broadcasted.

Dr. Yoo is Professor and Associate Director of the Wake Forest Institute for Regenerative Medicine (WFIRM), with cross-appointments to the Departments of Urology, Physiology and Pharmacology, Clinical and Translational Science Institute, and the Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences. He is also an elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE).

Dr. Yoo’s research efforts have been directed toward developing tissue engineering technologies and therapeutic approaches for clinical translation. A few notable examples of successful clinical translation include the bladder, urethra, vagina, and muscle cell therapy for incontinence.

Dr. Yoo has been a lead scientist in the bioprinting program at WFIRM and has been instrumental in developing skin bioprinting and integrated tissue and organ printing (ITOP) systems for preclinical and clinical applications.

He and his teams were recently awarded first and second place in NASA Centennial Vascular Tissue Challenge for bioprinting metabolically active thick liver tissue that retained function for thirty days.

Dr. Yoo has authored more than 340 scientific publications, 100 patent registrations/applications, 1000 scientific presentations, 310 invited lectures and mentored over 320 trainees, ranging from undergraduate students to practicing physicians

For further information contact: Angela.Losada@ehu.eus

• Read More

3D Printing and Bioprinting for Pharmaceutical and Medical Applications

Researchers of CIBER-BBN group NanoBioCell – NANBIOSIS U10 Drug Formulation unit Jose Luis Pedraz Muñoz, Laura Saenz del Burgo Martínez, Gustavo Puras Ochoa, Jon Zarate Sesma have edited the book “3D Printing and Bioprinting for Pharmaceutical and Medical Applications”

The increasing availability and decreasing costs of 3D printing and bioprinting technologies are expanding opportunities to meet medical needs. 3D Printing and Bioprinting for Pharmaceutical and Medical Applications discusses emerging approaches related to these game-changer technologies in such areas as drug development, medical devices, and bioreactors.

Key Features:

Offers an overview of applications, the market, and regulatory analysis
Analyzes market research of 3D printing and bioprinting technologies
Reviews 3D printing of novel pharmaceutical dosage forms for personalized therapies and for medical devices, as well as the benefits of 3D printing for training purposes
Covers 3D bioprinting technology, including the design of polymers and decellularized matrices for bio-inks development, elaboration of 3D models for drug evaluation, and 3D bioprinting for musculoskeletal, cardiovascular, central nervous system, ocular, and skin applications
Provides risk-benefit analysis of each application
Highlights bioreactors, regulatory aspects, frontiers, and challenges

This book serves as an ideal reference for students, researchers, and professionals in materials science, bioengineering, the medical industry, and healthcare.

For table of contents and further deatails:

3D Printing and Bioprinting for Pharmaceutical and Medical Applications. ISBN 9781032228662332 Pages 73 B/W Illustrations. Published September 27, 2023 by CRC Press

• Read More

Carlos Rodriguez-Abreu (NANBIOSIS U12) keynote speaker at the European Colloid and Interface Society ECIS 2023

Carlos Rodriguez-Abreu, Scientific Director of NANBIOSIS U12 Nanostructured liquid characterization unit gave a Keynote presentation entitled “Chromonic liquid crystal emulsions” at the European Colloid and Interface Society ECIS 2023 conference held in Naples, Italy (September 3-8, 2023) . Chromonic liquid crystals (CLC) can be used as templates for material synthesis and, since some CLC are nontoxic and water-based, they are also interesting for biological and medical applications. The presentation included a summary of experimental results on internally structured emulsions made of CLC encapsulated in droplets, that feature various complex morphologies. Photothermal, sensing and imaging applications are envisaged.

• Read More

2023 Annual Conference of CIBER-BBN and NANBIOSIS with CIBEREHD

CIBER-BBN´s and NANBIOSIS 2023 Annual Conference will be celebrated in November 6-8, 2023 in Santander

This year we change the format of our annual conferences towards a collective event scheme between the CIBER-BBN and CIBER-EHD thematic areas. Our objective is to create a two-day conference that stimulates scientific collaborations and explores new lines of research. Both areas have already shared experiences of collaborative projects, demonstrating the complementarity of their fields. The results of these seed projects will be presented on the first day. In addition, we are pleased to announce that there will be a new edition of seed collaborative projects between the two areas, which will open in the autumn, and close after the joint meeting.

The anual session dedicated to NANBIOSIS is scheduled for the afternoon of the Tuesday 7th, After that, we will cellebrate the annual meeting of the NANBIOSIS coordination Committee and the Scientific and Technical Advisory Board of NANBIOSIS.

We hope that you find the program attractive and that we can enjoy a few days of science, friendship, community, collaboration and discovery.

Click here to view the program and register

ICTS participation in the First guide to facilitate the sustainable design of printed electronic devices

Scientists of NANBIOSIS Unit 8 have participated in the publication of a a comprehensive experimental review of inks, paper substrates, and printing techniques. The objective is to offer the scientific community a guide with data to facilitate the design of printed devices and manufacture them in an ecological way.

Gemma Gabriel, researcher of Biomedical Applications Group at IMB-CNM and last author of the article, highlights the applications of the results in health monitoring, with non-invasive techniques such as glucose detection, although there are many applications where printed electronic materials and technologies are very useful. Among them, environmental monitoring, (in air and water quality control systems or detection of pollutants), in wearable electronics, such as flexible and lightweight devices that can be integrated into clothing, accessories or directly on the skin; energy harvesting and storage such as lightweight and flexible energy harvesting devices such as solar cells and thermoelectric generators; and the “Internet of Things (IoT)” with low-cost sensors that are easy to implement in smart home systems and industrial automation.

Implication of Unique Scientific and Tecnical Research Infraestructures
For the research, the team has used the Unit 8 of the ICTS NANBIOSIS of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) at the IMB-CNM-CSIC and the MICRONANOFABS network, the ICTS of clean rooms of micro and nanofabrication of which the IMB-CNM-CSIC is a part.

The research has been carried out within the ECOTRONIC projects, funded by the Ministry of Science and Innovation in the 2018 Innovation Challenges call, and CEL-SENS, within the framework of the Strategic Projects Oriented to the Ecological Transition and the Digital Transition financed by the Ministry with funds from the European Union ‘NextGenerationEU’/Plan for Recovery, Transformation and Resilience.

• Read More

NANBIOSIS receives the support of the Spanish Research Agency (Ministry of Science and Innovation) financing the NANBIO-ACCESS project, in the 2022 call for Excellence Research Networks.

Today has been published the Resolution of the Presidency of the State Research Agency of the Spanish Ministry for Science and Innovation granting fund for the selected projects in the 2022 call for “RESEARCH NETWORKS” within the framework of the State Program to Promote Scientific-Technical Research and its Transfer, of the State Research Plan Scientific, Technical and Innovation

The final resolution proposal was issued on June 21, 2023, once the hearing process has been completed and prior acceptance by the interested parties.

The two years lasting project 2021-2023RED2022-134685-I “NANBIO-ACCESS” was among the selected proposals.

The main goals pursued by the projects are:

1. Promote and consolidate the offer of the NANBIOSIS strategic services, which target advanced challenges in biomedical research: our Cutting-Edge Biomedical Solutions.

2. Promote the open and competitive access to NANBIOSIS services and, especially, to our strategic services.

3. Strengthen NANBIOSIS communication tools and enhance internationalization capabilities.

The proposed activities address the coordination within NANBIOSIS and the complementarity of the capacities of its units, optimizing its resources. Actions are especially proposed to promote the participation of NANBIOSIS nodes and units to the “Cutting-Edge Biomedical Solutions” program.

• Read More

Resolution of the 2nd competitive call of 2023 for access to NANBIOSIS

NANBIOSIS is a Research Infrastructure for Biomedicine made up of the Platforms of the Center for Centro de Ivesntigación Biomedica en Red (CIBER- in the area of Bioengineering, Biomaterials, and Nanomedicine -CIBER-BBN), the Preclinical Infrastructure and the Development of Minimally Invasive Technologies, of the Jesús Usón Minimally Invasive Surgery Center (CCMIJU) and the Nanoimaging unit of the Biomedical Research Institute of Malaga-Nanomedicine Platform (IBIMA-BIONAND Platform).

NANBIOSIS as part of the Spanish Map of ICTS (an acronym for “Scientific and Technical Unique Infrastructures” in Spanish), approved by the Ministry of Science and Innovation, is open to all interested national and international users who may come either from the public or the private sector, and who can apply for access under the “Competitive Open Access” or “Access on Demand” modalities.

The 20% of the NANBIOSIS Units’ capacity is granted on the Competitive Open Access modality and will be prioritized according to scientific and technical quality and singularity of the applictions.

Consult the Resolution and details here

Jesús Santamaría, Scientific Director of NANBIOSIS Unit 9, elected foreign member of the Istituto Lombardo Accademia di Science et Lettere

Jesús Santamaría, Professor of Chemical Engineering at the University of Zaragoza, has been elected a foreign member of the Istituto Lombardo Accademia di Science et Lettere, in its division of Mathematical and Natural Sciences, Chemistry section.

This institution was originally founded by Napoleon Bonaparte in 1797, as the National Institute of the Cisalpine Republic, in charge of collecting discoveries and perfecting the arts and sciences, following the model of the Institut de France. Napoleon himself appointed the first members of the Institute and its first president, Alesssandro Volta, Italian chemist and physicist, famous primarily for the discovery of methane in 1776 and the invention and development of the electric battery in 1799 .

Today the Istituto Lombardo depends on the Italian Ministry of Culture with headquarters in the Brera Palace, and has maintained its founding task of contributing to “issues related to education and public welfare. It currently develops a wide program of activities, including support for research in the fields of action of the institution, numerous events and public conferences, as well as its publications and the management of its famous archives and library.

Among the members who have belonged to the Istituto Lombardo are, in addition to Napoleon himself and Volta, the poet Vincenzo Monti, the writer and politician Alessandro Manzoni, the philosopher Carlo Cattaneo and the cleric Achille Ratti, future Pope Pius XI, as well as several Nobel Prize winners. : Camillo Golgi (Medicine), Giosuè Carducci (Literature), Giulio Natta (Chemistry) and Eugenio Montale (Literature).

Professor Santamaría has a long and profuse career in the academic and scientific field, with 370 published articles, 35 doctoral theses supervised, 26 patents and participation in 18 European projects, including two of the prestigious Advanced Grants from the European Research Council (ERC),. Jesús Santamaría is the Principal Investigator of the NFP (Nanostructured Films and Particles) research group, that belongs to the Aragon Institute of Materials and Nanoscience (INMA), CSIC-UNIZAR joint center, the Aragon Health Research Institute (IIS Aragon), and the Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). He is also the Scientific Director of NANBIOSIS U9 “Synthesis of Nanoparticles Unit” since its creatrion in 2007 by UNIZAR and CIBER-BBN, recognized by the Spanish Governmen as “Unique Scientific and Technical Infraestructure” (ICTS in Spanish) .

Santamaría has been director of the Samca Chair of Nanotechnology, deputy director of the Unizar Nanoscience Institute of Aragon and editor of the Chemical Engineering Journal. He has carried out postdoctoral research stays at the University of Notre Dame and at the Massachusetts Institute of Technology (MIT), both in the United States.

His current research topics include the development of new methods for the synthesis of nanomaterials, and applications of the synthesized materials in medicine, photo-assisted catalysis, microwave catalysis, molecular recognition sensing, and nanosafety.

• Read More

Nanbiosis

You are here : Home / 2023 (Page 2)